School of Medicine
Showing 1-2 of 2 Results
Clinical Assistant Professor, Ophthalmology
BioDr. Ramsudha Narala is a board certified ophthalmologist who specializes in vitreoretinal surgery and ocular oncology. Dr. Narala grew up in Fresno, California and following high school, she attended the 8 year combined undergraduate-medical school program at Saint Louis University in Saint Louis, Missouri.
After medical school, she completed her ophthalmology residency at Kresge Eye Institute in Detroit, MI, where she received the best resident teacher award and highest resident ophthalmic knowledge assessment program exam score award. She then joined the University of Southern California in Los Angeles, California for a 2 year vitreoretinal surgery fellowship where she was elected chief vitreoretinal surgery fellow. Following completion of vitreoretinal surgery fellowship, she pursued an advanced training fellowship in ocular oncology at Byers Eye Institute at Stanford University.
Dr. Narala has authored many peer-reviewed scientific publications and textbook chapters on vitreoretinal diseases and ocular oncology. She is also dedicated to education and teaching medical students, residents, and fellows.
Dr. Narala's clinical practice is mainly based at Santa Clara Valley Medical Center.
Quan Dong Nguyen, MD, MSc
Professor of Ophthalmology and, by courtesy, of Pediatrics and of Medicine (Immunology & Rheumatology)
Current Research and Scholarly InterestsWe have focused our research on the development of novel therapies and innovative assessment and diagnostic imaging technologies for retinal vascular and ocular inflammatory disorders, specifically diabetic retinopathy (DR), age-related macular degeneration (AMD) and uveitis. Building on our initial work describing the role of hypoxia and vascular endothelial growth factor (VEGF) in diabetic retinopathy (DR) and diabetic macular edema (DME), We have become interested in the biochemical mechanisms that would presumably lead to DME. During the past decade, our research has contributed to the body of evidences that defines the important role of anti-VEGF therapies in DME and AMD, as well as the role of the mTOR pathway and various interleukins in the pathogenesis of uveitis.
We have launched a productive and well-funded clinical research program while at the same time providing clinical care to patients with uveitis and retinal vascular diseases and fulfilling significant teaching and administrative assignments. We have established a number of key collaborators both within and outside the institutions. In addition, we have also established Center in Baltimore and now in Silicon Valley, which has excelled in conducting proof-of concept, early-phase multi-center clinical trials and studies, exploring the clinical disease manifestations and the efficacy of various pharmacologic agents in retinal, uveitic, and ocular inflammatory disorders.